-
Mashup Score: 11Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms - 14 hour(s) ago
Key Points. Exposure to thalidomide analogs, particularly lenalidomide, is associated with increased risk of TP53-mutated myeloid neoplasms.Treatment with lenal
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 48Second-Line Belantamab Mafodotin in Multiple Myeloma: Will These DREAMMs Become Reality? - 1 day(s) ago
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this article, the authors describe how they expect belantamab mafodotin to be used and how the drug’s ocular toxicities may be managed if the drug regains regulatory approval.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Thanks @ASCO Daily News for taking a chance on this paper from #dorishansen & me 🙏🏽 When belantamab gets re-approved (already re-approved in 🇬🇧) for #MMsm, how might MDs dose it to maximize efficacy & safety? Our Bela-Vd and Bela-Pd suggestions ⬇️ https://t.co/sTuZx9fem0 https://t.co/Csiqdu7QTQ
-
-
Mashup Score: 48Second-Line Belantamab Mafodotin in Multiple Myeloma: Will These DREAMMs Become Reality? - 2 day(s) ago
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this article, the authors describe how they expect belantamab mafodotin to be used and how the drug’s ocular toxicities may be managed if the drug regains regulatory approval.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Thanks @ASCO Daily News for taking a chance on this paper from #dorishansen & me 🙏🏽 When belantamab gets re-approved (already re-approved in 🇬🇧) for #MMsm, how might MDs dose it to maximize efficacy & safety? Our Bela-Vd and Bela-Pd suggestions ⬇️ https://t.co/sTuZx9fem0 https://t.co/Csiqdu7QTQ
-
-
Mashup Score: 2
Yelak Biru: Rahul Banerjee on redefining ‘cure’ in myeloma / cancer, Myeloma, OncoDaily, Oncology, Rahul Banerjee, Yelak Biru
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @oncodaily: Rahul Banerjee on redefining 'cure' in myeloma - Yelak Biru (@NorthTxMSG) @RahulBanerjeeMD https://t.co/wpmn7fLidb #OncoDa…
-
-
Mashup Score: 3UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM Patients - 16 day(s) ago
UK Medicine and Healthcare products Regulatory Agency (MHRA) authorizes use of Blenrep (belantamab mafodotin) for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.
Source: www.myeloma.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @JoshuaRichterMD: UK MHRA Approves Blenrep Combinations for RRMM| Int'l Myeloma Fn. #mmsm @IMFmyeloma https://t.co/lruxVQNDLX
-
-
Mashup Score: 5
The management of multiple myeloma (MM) is becoming increasingly more complex. The approval of novel treatment approaches provides much-needed opportunities but also raises questions and controversies about how to optimally sequence therapies and select treatments for individual patients.
Categories: General Medicine News, Partners & KOLsTweet-
Link to article: https://t.co/8ySoGBpmKy Of course will be outdated in a few years, but it was fun to discuss these topics with everyone and write this -thanks @AjaiChari for leading! https://t.co/Etp2rzpmJ0
-
-
Mashup Score: 1Understanding Real-World Data vs. Evidence #BloodCancers - 23 day(s) ago
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversityCreate a free account to track your progress, bookmark less…
Source: www.youtube.comCategories: General Medicine News, Partners & KOLsTweet-
RT @MyelomaTeacher: Understanding Real-World Data vs. Evidence #BloodCancers https://t.co/waZzcI8kWd #mmsm @HealthTree @RahulBanerjeeMD
-
-
Mashup Score: 1A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up - 24 day(s) ago
Key Points. FCARH143 achieved a 100% ORR, with 68% sCR and a median PFS of 15.5 months at 67.3 months follow-up.Toxicity was manageable, with no grade ≥3 I
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
Paper in Blood: https://t.co/9DXdkWnOJG
-
-
Mashup Score: 13
Hematology Pills · Episode
Source: open.spotify.comCategories: General Medicine News, Partners & KOLsTweet-
Thank you Prof. Foa & @fmilano976 for invite to "Hematology Pills" re: CAR-T in myeloma #MMsm... Who really needs 2nd-line CAR-T and how do we make it safer? 🇮🇹-themed podcast with shoutouts about @RobertoMinaMD, Torino, and his PRO research here! https://t.co/kaJyEoogK9 https://t.co/fM5XfOnSsj
-
-
Mashup Score: 1A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up - 25 day(s) ago
Key Points. FCARH143 achieved a 100% ORR, with 68% sCR and a median PFS of 15.5 months at 67.3 months follow-up.Toxicity was manageable, with no grade ≥3 I
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
Paper in Blood: https://t.co/9DXdkWnOJG
-
6/ One other paper worth mentioning in this thread. Tour de force @BloodJournal paper by @adamssperling et al about lenalidomide and the risk of TP53-mutated myeloid neoplasms such as MDS/AML. Interestingly, pom (and hopefully CELMoDs) don't do this! https://t.co/a9ApPfvVk4